CatalystFDA/Bio

J&J reports 75% tumor response rate with novel prostate cancer therapy

J&J's novel prostate cancer therapy achieved a 75% tumor response rate.

What changed

J&J's novel prostate cancer therapy achieved a 75% tumor response rate.

Why it matters

J&J's novel prostate cancer therapy achieved a 75% tumor response rate. — impact context not separately stored; see What changed.

Sources